Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.

Nishijima T, Hamada Y, Watanabe K, Komatsu H, Kinai E, Tsukada K, Teruya K, Gatanaga H, Kikuchi Y, Oka S.

PLoS One. 2013 Oct 10;8(10):e77268. doi: 10.1371/journal.pone.0077268. eCollection 2013.

2.

High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.

Hamada Y, Nishijima T, Watanabe K, Komatsu H, Tsukada K, Teruya K, Gatanaga H, Kikuchi Y, Oka S.

Clin Infect Dis. 2012 Nov;55(9):1262-9. doi: 10.1093/cid/cis621. Epub 2012 Jul 19.

PMID:
22820542
3.

Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?

Hamada Y, Nishijima T, Komatsu H, Teruya K, Gatanaga H, Kikuchi Y, Oka S.

PLoS One. 2013 Jul 16;8(7):e69845. doi: 10.1371/journal.pone.0069845. Print 2013.

4.

Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.

Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson M.

AIDS. 2011 Aug 24;25(13):1671-3. doi: 10.1097/QAD.0b013e32834a1cd6.

PMID:
21716074
5.

Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.

Tinago W, O'Halloran JA, O'Halloran RM, Macken A, Lambert JS, Sheehan GJ, Mallon PW.

HIV Med. 2014 Apr;15(4):224-32. doi: 10.1111/hiv.12107. Epub 2013 Nov 12.

6.

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.

Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES study team.

AIDS. 2010 Aug 24;24(13):2019-27. doi: 10.1097/QAD.0b013e32833bee1b.

PMID:
20613461
7.

Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.

Overton ET, Tebas P, Coate B, Ryan R, Perniciaro A, Dayaram YK, De La Rosa G, Baugh BP.

HIV Clin Trials. 2016 Mar;17(2):72-7. doi: 10.1080/15284336.2016.1141468.

8.

Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.

Foglia E, Bonfanti P, Rizzardini G, Bonizzoni E, Restelli U, Ricci E, Porazzi E, Scolari F, Croce D.

PLoS One. 2013;8(2):e57777. doi: 10.1371/journal.pone.0057777. Epub 2013 Feb 27. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/e57d7e73-826c-4e1c-a7c6-d2c32d3809af.

9.

High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients.

de Lastours V, Ferrari Rafael De Silva E, Daudon M, Porcher R, Loze B, Sauvageon H, Molina JM.

J Antimicrob Chemother. 2013 Aug;68(8):1850-6. doi: 10.1093/jac/dkt125. Epub 2013 Apr 18.

PMID:
23599359
10.

Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.

Rodríguez-Nóvoa S, Morello J, Barreiro P, Maida I, García-Gascó P, Vispo E, González-Pardo G, Parra A, Jiménez-Nácher I, Soriano V.

AIDS Res Hum Retroviruses. 2008 Jun;24(6):821-5. doi: 10.1089/aid.2007.0276.

PMID:
18507524
11.

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.

Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M, Van de Casteele T, Tomaka F.

HIV Med. 2013 Jan;14(1):49-59. doi: 10.1111/j.1468-1293.2012.01060.x. Epub 2012 Oct 23.

12.

Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection.

Jansen K, Sönnerborg A, Brockmeyer N, Thalme A, Svedhem V, Dupke S, Eychenne JL, Nakonz T, Jimenez-Exposito MJ, Pugliese P.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):564-73. doi: 10.1089/AID.2012.0092. Epub 2012 Nov 27.

13.

Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.

Aberg JA, Tebas P, Overton ET, Gupta SK, Sax PE, Landay A, Falcon R, Ryan R, De La Rosa G.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1184-95. Epub 2012 Apr 2.

14.

Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens.

Castagna A, Galli L, Gianotti N, Torti C, Antinori A, Maserati R, d'Arminio Monforte A, Quiros-Roldan E, Salpietro S, Lazzarin A.

New Microbiol. 2013 Jul;36(3):239-49. Epub 2013 Jun 30.

15.

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.

Rusconi S, Giacomet V, Mameli C, Viganò A, Viganò O, Adorni F, Galli M, Zuccotti GV.

BMC Infect Dis. 2012 Aug 6;12:179. doi: 10.1186/1471-2334-12-179.

16.

Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.

Calza L, Trapani F, Salvadori C, Magistrelli E, Manfredi R, Colangeli V, Di Bari MA, Borderi M, Viale P.

Scand J Infect Dis. 2013 Feb;45(2):147-54. doi: 10.3109/00365548.2012.712213. Epub 2012 Sep 19.

PMID:
22991923
17.

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari Ed, Gatell JM; ATAZIP Study Group.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):29-36. doi: 10.1097/QAI.0b013e31819a226f.

PMID:
19390327
18.

Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice.

Antoniou T, Raboud JM, Diong C, Su D, Dewhurst N, Buckley V, Kovacs C, Rachlis A, Brunetta J, Smith G, Gough K, Fletcher D, Loutfy MR.

J Int Assoc Physicians AIDS Care (Chic). 2010 Nov-Dec;9(6):382-9. doi: 10.1177/1545109710382041.

PMID:
21138833
19.

A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.

Dejesus E, Mills A, Bhatti L, Conner C, Storfer S.

Int J Clin Pract. 2011 Dec;65(12):1240-9. doi: 10.1111/j.1742-1241.2011.02807.x. Epub 2011 Oct 14.

PMID:
21999631
20.

Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin.

Auclair M, Afonso P, Capel E, Caron-Debarle M, Capeau J.

Antivir Ther. 2014;19(8):773-82. doi: 10.3851/IMP2752. Epub 2014 Feb 17.

PMID:
24535489

Supplemental Content

Support Center